- Osteoarthritis ("OA") is the leading cause of disability in
older adults.
- The U.S. Centers for Disease Control and Prevention estimates
that knee OA affects more than 30 million people in the U.S.
alone.
- Registration for the webinar now open to the public.
VICTORIA, BC, July 3, 2024
/PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the
"Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage
biotechnology company leveraging its proprietary DiffuSphere™
technology to optimize drug delivery for applications with
significant unmet need, today announced that Eupraxia's CEO, Dr.
James A. Helliwell, will present at
a Tribe Public Webinar Presentation and Q&A Event titled,
"Exploring The Rapid Rise of Osteoarthritis".
The event is scheduled to begin at 8:30
am PT / 11:30 am ET on
Tuesday, July 9, 2024.
To register to join the complimentary event, please visit Tribe
Public at: EPRXJuly92024.TribePublic.com.
Once registered, participants may begin forwarding their
questions for Dr. Helliwell to Tribe Public at
research@tribepublic.com, or share their questions via the ZOOM
chat feature during the event. Tribe Public's Managing Member,
John F. Heerdink, Jr., will host the
event and relay all questions to management.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology designed to deliver targeted,
long-lasting activity with fewer side effects. DiffuSphere™, a
proprietary, polymer-based micro-sphere technology, is designed to
facilitate targeted drug delivery, with extended duration of
effect, and offers multiple, highly tuneable pharmacokinetic (PK)
profiles. This investigational technology can be engineered for use
with multiple active pharmaceutical ingredients and delivery
methods.
Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for
the treatment of pain due to osteoarthritis of the knee. The trial
met its primary endpoint and three of the four secondary endpoints.
Eupraxia has expanded the EP-104 platform into gastrointestinal
disease with the Phase 1b/2a RESOLVE
trial for treating eosinophilic esophagitis. Eupraxia is also
developing a pipeline of later- and earlier-stage long-acting
formulations. Potential pipeline indications include candidates for
other inflammatory joint indications and oncology, each designed to
improve on the activity and tolerability of currently approved
drugs. For further details about Eupraxia, please visit the
Company's website at: www.eupraxiapharma.com.
About Tribe Public LLC
Tribe Public LLC is a San Francisco,
CA-based organization that hosts complimentary worldwide
webinar & in-person meeting events in the U.S. Tribe's
complimentary events focus on issues that the Tribe members care
about with an emphasis on hosting management teams from publicly
traded companies from all sectors & financial organizations
that are seeking to increase awareness of their products, progress
and plans. Tribe members primarily include Family Offices,
Portfolio Managers, Registered Investment Advisors, Accredited
Investors, Sell Side Analysts, and members of media. Tribe Members
are encouraged to express their interest in speakers they care
about and want to learn from at the Tribe Public website via the
Tribe's FREE "Wish List" process. Visit Tribe Public's Website to
learn more: http://www.tribepublic.com.
Notice Regarding Forward-looking Statements and
Information
This news release includes forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "suggests", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes", "potential"
or variations (including negative and grammatical variations) of
such words and phrases, or state that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved. Forward looking statements in this news release
include statements regarding Tribe Public's webinar event; the
Company's product candidates, including expected benefits to
patients with respect to safety, efficacy, duration and
tolerability; the results gathered from studies and trials of
Eupraxia's product candidates; the potential for the Company's
technology to impact the drug delivery process; potential market
opportunity for the Company's products, and potential pipeline
indications. Such statements and information are based on the
current expectations of Eupraxia's management, and are based on
assumptions, including but not limited to: future research and
development plans for the Company proceeding substantially as
currently envisioned; industry growth trends, including with
respect to projected and actual industry sales; the Company's
ability to obtain positive results from the Company's research and
development activities, including clinical trials; and the
Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties
related to the Company's limited operating history; the Company's
novel technology with uncertain market acceptance; if the Company
breaches any of the agreements under which it licenses rights to
its product candidates or technology from third parties, the
Company could lose license rights that are important to its
business; the Company's current license agreement may not provide
an adequate remedy for its breach by the licensor; the Company's
technology may not be successful for its intended use; the
Company's future technology will require regulatory approval, which
is costly and the Company may not be able to obtain it; the Company
may fail to obtain regulatory approvals or only obtain approvals
for limited uses or indications; the Company's clinical trials may
fail to demonstrate adequately the safety and efficacy of our
product candidates at any stage of clinical development; the
Company may be required to suspend or discontinue clinical trials
due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for
its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical
research services; the Company may not be able to successfully
execute its business strategy; the Company will require additional
financing, which may not be available; any therapeutics the Company
develops will be subject to extensive, lengthy and uncertain
regulatory requirements, which could adversely affect the Company's
ability to obtain regulatory approval in a timely manner, or at
all; the impact of health pandemics or epidemics on the Company's
operations; the Company's restatement of its consolidated financial
statements, which may lead to additional risks and uncertainties,
including loss of investor confidence and negative impacts on the
Company's common share price; and other risks and uncertainties
described in more detail in Eupraxia's public filings on SEDAR+
(sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-ceo-dr-james-helliwell-to-participate-in-webinar-event-exploring-the-rapid-rise-of-osteoarthritis-on-july-9-2024-302189221.html
SOURCE Eupraxia Pharmaceuticals Inc.